Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 12, 2025 08:22 ET | Source: Magstim EGI

FDA Clears Magstim Magnetic Stimulation for Chronic Pain Treatment

Millions living with chronic pain now have a new, FDA-cleared, non-invasive, and drug-free treatment option with Magstim Magnetic Stimulation.
November 10, 2025 09:00 ET | Source: Femasys Inc.

Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe

-- Continued rollout of FemBloc, the breakthrough non-surgical permanent contraceptive solution, expands the Company’s presence in key European Markets -- ATLANTA, Nov. 10, 2025 (GLOBE NEWSWIRE) --...
November 03, 2025 08:30 ET | Source: Femasys Inc.

Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million

-- Successful completion of first trial phase enables continued pivotal trial of FemBloc, the only non-surgical permanent birth control, toward U.S. FDA approval -- -- $12 million senior secured...
October 22, 2025 09:00 ET | Source: Femasys Inc.

Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe

--Marks key milestone in European commercialization strategy under EU Medical Device Regulation (MDR)-- ATLANTA, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical...
September 26, 2025 08:43 ET | Source: ADvantage Therapeutics, Inc.

UPDATE -- ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic

ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic
September 26, 2025 06:52 ET | Source: ADvantage Therapeutics, Inc.

ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic

ADvantage Therapeutics Awarded $2.5 milion NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic
September 11, 2025 09:00 ET | Source: Femasys Inc.

Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

ATLANTA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective...
August 04, 2025 06:00 ET | Source: BioCardia, Inc.

BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter

SUNNYVALE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
June 23, 2025 08:15 ET | Source: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236

SOUTH SAN FRANSCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an immunotherapy company developing the next generation of...
June 17, 2025 09:00 ET | Source: Femasys Inc.

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

--New CCO to Lead U.S. Commercialization of Fertility Products, Including FemaSeed®, and Expand Strategic Global Partnerships Across Full Portfolio-- ATLANTA, June 17, 2025 (GLOBE NEWSWIRE)...